Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-022506
Filing Date
2025-08-20
Accepted
2025-08-20 17:28:07
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 40754
2 TRANSACTIONS RELATING TO THE ORDINARY SHARES OF THE ISSUER DURING THE PAST SIXTY ex-10-08202025_090809.htm EX-10.1 30573
3 JOINT FILING AGREEMENT ex-99-08202025_090811.htm EX-99.1 15539
  Complete submission text file 0001415889-25-022506.txt   88670
Mailing Address 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Business Address 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 (206) 621-7200
Frazier Life Sciences X, L.P. (Filed by) CIK: 0001790879 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Subject) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93833 | Film No.: 251237841
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)